1EMA. Committee for Medicinal Products for Veterinary Use [DB/OL]. EMA/CV:/417654/2014. http://wvcw, ema. eu- ropa eu/docs/en GB/documentlibrary/MaximumResidue Limits-Summary_of_opinion/2014/O7/WC50016976: pd:. 被引量：1
2EMA. European Public Assessment Report(EPAR).ZACTRAN. EPAR summary for the public [DB/OL].EMEA/V/C/129. http://www, emaeuropa eu/docs/en_GB/document library/ EPAR_-_Summary_for_the public/veterinary/O00129/ WC 500068714. pdf. 被引量：1
4MenningerJR. Functional consequences of binding mac- rolidesto ribosomes[J].Journal of Antimicrobial Ch- emotherapy, 1985,16(Suppl. A):23-34. 被引量：1
5JainR, Danziger L H. The macrolide antibiotics:a pha- rmacokinetieand pharmacodynamic overview [J].Current PharmaceuticalDesign, 2004,10(25):3045-3053. 被引量：1
6Forbes A B, Ramage Q Sales : et al. Determination of the Duration of Antibacterial Efficacy following Admin- istration of Gamithromycin Using a Bovine Mannheimia haemolytica Challenge Model[J].Antimicrobial Agents And Chemotherapy, 2011,55(2):831-835. 被引量：1
7Lechtenberg K, Daniels C S, Royer G C, et al. Field ef- ficacy study of gamithromycin for the control of bovine respiratory disease in cattle at high risk of developing the disease[J].Intern 7 Appl Res Vet Med, 2011,9(2):184-192. 被引量：1
8Huang R A, Letendre L T, Banav N, et al. Pharmacokinet- ics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity [J].7ournal of Veterinary Pharmacology and Therapeutics, 2010,33(3):227-237. 被引量：1
9Wyns H, Meyer E, Plessers E, et al. Pharmacokinetics of gamithromycin after intravenous and subcutaneous a- dministration in pigs[J].Research in Veterinary Sc- ience, 2014,96(1):160-163. 被引量：1
10Berghaus L J, Giguere S, Sturgill T L, et al. Plasma pharmacokinetics, pulmonary distribution and in vitro activity of gamithromycin in foals [J]. Journal of Veterinary Pharmacology and Therapeutics, 2012,35 (1):59-66. 被引量：1
